Stockscreener 앱 받기
0.3501
21.94%
-0.0984
전일 마감가:
$0.4485
열려 있는:
$0.435
하루 거래량:
1.76M
Relative Volume:
2.18
시가총액:
$4.99M
수익:
-
순이익/손실:
$-6.07M
주가수익비율:
-0.0606
EPS:
-5.78
순현금흐름:
$-7.34M
1주 성능:
-38.78%
1개월 성능:
-44.78%
6개월 성능:
-67.88%
1년 성능:
-73.03%
1일 변동 폭
$0.35
$0.4396
1주일 범위
$0.35
$0.60
52주 변동 폭
$0.35
$3.00
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
명칭
Adial Pharmaceuticals Inc
전화
434-422-9800
주소
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
ADIL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
0.3501 | 4.99M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
| 2018-10-30 | 개시 | Maxim Group | Buy |
| 2018-10-11 | 개시 | Dawson James | Buy |
Adial Pharmaceuticals Inc 주식(ADIL)의 최신 뉴스
ADIL Stock on the Rise: A Promising Investment - investchronicle.com
EXCLUSIVE: Intelligent Bio Solutions Expands US Forensic Market Presence, Seeks FDA Clearance For Fingerprint Drug Testing - AOL.com
Adial Pharmaceuticals advances Phase 3 trial design for alcohol disorder drug - Investing.com
Adial Pharmaceuticals (ADIL) Advances Phase 3 Trial Plans for AD04 | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04 - GlobeNewswire
Revolutionary AI-Powered Phase 3 Trial: How Adial Plans to Transform Alcohol Addiction Treatment - Stock Titan
EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial - Benzinga
ADIL: A.G.P./Alliance Global Partners Appointed as Sole Placement Agent | ADIL Stock News - GuruFocus
Adial Pharmaceuticals (ADIL) Files to Sell Over 6 Million Shares - GuruFocus
Adial Pharmaceuticals Faces Nasdaq Non-Compliance Notice - TipRanks
Adial Pharmaceuticals (ADIL) Files to Sell Over 6 Million Shares | ADIL Stock News - GuruFocus
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
ADIL Q2 EPS Increased by Brookline Capital Management - Defense World
Adial Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Adial Pharmaceuticals sets new proposal deadline By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals sets new proposal deadline - Investing.com
Adial Pharmaceuticals (ADIL) Reports Q1 2025 Results | ADIL Stoc - GuruFocus
Adial Pharmaceuticals Reports First Quarter 2025 Financial Resul - GuruFocus
Adial Pharmaceuticals (ADIL) Reports Q1 2025 Results | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Q1 2025 Financial Results and Business Update - TradingView
Adial Pharmaceuticals Advances AUD Drug to Phase 3, Cuts Losses by 66% in Q1 2025 Earnings - Stock Titan
ADIAL PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Adial Pharmaceuticals (ADIL) Receives Milestone Payment for Asth - GuruFocus
Adial Pharmaceuticals (ADIL) Receives Milestone Payment for Asthma Drug Development | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study - The Manila Times
Adial Pharmaceuticals (ADIL) Projected to Post Quarterly Earnings on Tuesday - Defense World
FDA to Review Adial’s Phase 3 Trial Plan for AUD Treatment - Investing.com Nigeria
FDA Has Granted Request for End of Phase 2 Meeting to Discuss Alcohol Use Disorder Treatment, AD04 - Psychiatric Times
FDA to Review Adial’s Phase 3 Trial Plan for AUD Treatment By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Granted End Of Phase 2 Meeting From FDA - marketscreener.com
EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program - AOL.com
Adial Pharmaceuticals (ADIL) Receives FDA Green Light for Phase 3 Meeting | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration - The Manila Times
Renaissance Technologies LLC Purchases New Stake in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) - Defense World
Richmond InnoAdial Pharmaceuticals raises $2.75M - The Business Journals
Biotech Alert: Searches spiking for these stocks today - TipRanks
ADIL: Adial Pharmaceuticals Boosts Patent Portfolio with New Approval | ADIL Stock News - GuruFocus
Geode Capital Management LLC Grows Stock Holdings in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) - Defense World
Adial Pharmaceuticals secures $2.75 million through warrant exercise By Investing.com - Investing.com Nigeria
Press Release Distribution & PR Platform - ACCESS Newswire
Adial Pharmaceuticals secures $2.75 million through warrant exercise - Investing.com
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds - GlobeNewswire
Healthcare Investor Commits $2.75M to Adial Pharmaceuticals Addiction Treatment Pipeline - Stock Titan
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring - Asianet Newsable
Adial Pharmaceuticals Inc: Rising -76.71% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
How will Adial Pharmaceuticals Inc’s (ADIL) earnings compare to estimates this quarter? - uspostnews.com
Adial Pharmaceuticals (ADIL) Secures Patent for Novel Addiction Treatment Method | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Inc (ADIL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):